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ABSTRACT
Objective: We conducted a community survey to estimate the prevalence and describe the fea-
tures, risk factors, and consequences of convulsive status epilepticus (CSE) among people with
active convulsive epilepsy (ACE) identified in a multisite survey in Africa.
Methods:We obtained clinical histories of CSE and neurologic examination data among1,196people
with ACE identified from a population of 379,166 people in 3 sites: Agincourt, South Africa; Iganga-
Mayuge, Uganda; and Kilifi, Kenya. We performed serologic assessment for the presence of antibod-
ies to parasitic infections and HIV and determined adherence to antiepileptic drugs. Consequences of
CSE were assessed using a questionnaire. Logistic regression was used to identify risk factors.
Results: The adjusted prevalence of CSE in ACE among the general population across the 3 sites
was 2.3 per 1,000, and differed with site (p , 0.0001). Over half (55%) of CSE occurred in
febrile illnesses and focal seizures were present in 61%. Risk factors for CSE in ACE were
neurologic impairments, acute encephalopathy, previous hospitalization, and presence of anti-
body titers to falciparum malaria and HIV; these differed across sites. Burns (15%), lack of edu-
cation (49%), being single (77%), and unemployment (78%) were common in CSE; these differed
across the 3 sites. Nine percent with and 10% without CSE died.
Conclusions: CSE is common in people with ACE in Africa; most occurs with febrile illnesses, is
untreated, and has focal features suggesting preventable risk factors. Effective prevention and
the management of infections and neurologic impairments may reduce the burden of CSE in
ACE. Neurology® 2015;84:1838–1845
GLOSSARY
ACE 5 active convulsive epilepsy; AED 5 antiepileptic drug; BMI 5 body mass index; CI 5 confidence interval; CSE 5
convulsive status epilepticus; KDH 5 Kilifi District Hospital; OR 5 odds ratio.
Convulsive status epilepticus (CSE) is a common and serious complication of epilepsy and of
acute symptomatic and febrile seizures. It occurs in 25%–30% of people with active convulsive
epilepsy (ACE)1,2 and is dependent upon the underlying etiology and adherence to antiepileptic
drugs (AEDs).3 CSE among people with epilepsy in the United States is associated with a long-
term case fatality of over 20%.4
ACE is common in Africa,5 and the proportion with CSE is higher given the underlying
etiology and large treatment gap.6 There are few population-based studies of CSE in Africa, and
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most of the available hospital-based studies
probably underestimate the burden. The inci-
dence of CSE in children admitted to a Ken-
yan hospital was 2–5 times that in London
and 6% of these cases occurred in children
with established epilepsy6,7; many do not
attend hospital.
Risk factors for CSE are widely studied,8
but it is unclear whether these differ in ACE
in Africa. The few available studies from devel-
oped countries have focused on epilepsy-
related risk factors of CSE1; other infectious
risk factors of CSE may be important among
people with epilepsy from low-income coun-
tries, where the etiology of epilepsy is different
and the treatment gap is high.9 The clinical
features of CSE and medical and psychosocial
consequences may also differ.
We documented the medical history of
CSE among people with ACE in 3 African
sites to estimate the lifetime prevalence, deter-
mine associations with risk factors and clinical
features, and examine case fatality, burns, and
social factors. We further examined whether
there was heterogeneity in clinical features
and risk factors across different ecological sites.
METHODS Study population. Cases of CSE were identified
in community surveys of ACE conducted between August 2008
and April 2011 as part of a multisite study of epilepsy.5 The
present analysis includes 3 sites: Agincourt, South Africa; Iganga,
Uganda; and Kilifi, Kenya (http://www.indepth-network.org/),
where reliable histories of CSE among people with ACE were
obtained. Histories of CSE among people with ACE were
obtained from the participants, relatives, or witnesses, with
further questions on whether CSE was associated with a febrile
illness or fever. A clinician obtained data on sociodemographic
characteristics and medical history and performed a neurologic
examination. Experienced EEG technicians performed a 16 lead-
channel EEG using the standard 10–20 montage system
(figure 1), read by an experienced EEG technician (E.C.) in
consultation with a neurophysiologist (S.W.), who reviewed
some recordings to confirm consistency. We followed up
individuals with CSE for a further 3 years to observe survivorship.
Definition of terms. We defined CSE as a history of convulsive
seizures lasting for 30 minutes or more with impaired conscious-
ness, or intermittent seizures lasting for 30 minutes or more with-
out regaining consciousness in between the seizures.10 The
definitions utilized culturally appropriate events to time the seiz-
ures for those without watches or mobile phones, such as whether
a seizure lasted longer than the time taken to boil a pot of maize,
duration of a news program, or religious sermon, all of which last
$30 minutes.
We classified epileptic seizures as focal, generalized, or others
according to recent International League Against Epilepsy recom-
mendations.11 We categorized seizure frequency into daily,
weekly, monthly, or yearly.
We defined children as those aged 0–18 years. We defined a
perinatal adverse event as delay in crying, breathing, or breastfeed-
ing after birth, but was included only in those aged 18 years and
below, to reduce recall bias. We defined acute encephalopathy as
coma related to an acute malarial, viral, or bacterial illness. Cog-
nitive impairment was based on ability to follow standardized
instructions during neurologic examination. We defined malnu-
trition as height for age z scores below 22 for those 0–10 years,
body mass index (BMI) (weight/height2) in the lower 5th per-
centile for those 11–19 years, and BMI ,18.5 for adults.2,12
Investigations. In a random proportion of people [selected by
RAND () command in MySQL (Oracle, Redwood Shores,
CA)] with ACE and a history of CSE (figure 1), G.K. analyzed
blood for antibodies to Onchocerca volvulus, HIV, Taenia solium,
Toxocara canis, Plasmodium falciparum schizonts, and Toxoplasma
gondii. The commercial kits, technique used, cut-off criteria, and
sensitivities and specificities associated with detection of each
organism were described previously.13 Adherence to AEDs was
measured in blood using a technique described previously.14
Figure 1 Investigations performed in convulsive status epilepticus in active convulsive epilepsy
People with convulsive status epilepticus (CSE) in active convulsive epilepsy (ACE) who had EEG performed, and antiepilep-
tic drug (AED) blood levels and antibody titers to parasitic infections and HIV determined. ACE5 active convulsive epilepsy;
IgG 5 immunoglobulin G.
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Statistical analysis. We estimated the prevalence of CSE asso-
ciated with ACE for each center by dividing the number of con-
firmed cases of CSE by the total number of individuals screened
in the survey. The prevalence was adjusted for the sensitivity of
the methodology used to identify people with ACE.15 In Kilifi,
we compared the community estimates with admissions during or
prior to the survey using the Kilifi Health and Demographic
Surveillance System database, which offers a framework for link-
ing hospital and population data for each person.16
We compared those with CSE in ACE with those with ACE
without CSE. Pearson x2 test was used to compare proportions
while Student t test or Mann-Whitney, where appropriate, was used
to compare continuous variables between groups. Up to 774 people
with ACE without CSE were included in the risk factor analysis
(table e-1 on theNeurology® Web site at Neurology.org). We used a
logistic regression model that included age, sex, site, education, and
marital status of parents to compute odds ratios (ORs) for each risk
factor. All infections were entered together into the adjusted logistic
model to examine their independent association with CSE in ACE.
We considered a p value of#0.05 significant. Consequences of CSE
in those with ACE were compared first with those with ACE with-
out CSE and then with age group–matched community controls
without ACE (n 5 1,025 for the 3 sites) (table e-1).
Standard protocol approvals, registrations, and patient
consents. This project was approved by the Kenyan National
Ethical Review Committee as well as the respective Institutional
Review Boards in Uganda and South Africa. Written informed
consent was sought from people with epilepsy or caregivers.
RESULTS We identified 422 cases of CSE out of
1,196 people with ACE across the 3 sites, of which
256/422 (61%) occurred in children (,18 years)
and 211/422 (50%) in males. The majority of the
cases of CSE in ACE were drawn from Kilifi (254/
422 [60%]), with the remainder from Agincourt and
Iganga (table 1). Over half (230/422 [55%]) of the
reported CSE cases occurred with a febrile illness and
this was similar in generalized and focal epilepsy (p5
0.4). The overall adjusted prevalence of CSE associ-
ated with ACE among the general population across
the sites was 2.3 per 1,000, being highest in Iganga
(2.8 per 1,000) (table 1), and was greatest in adoles-
cents and young adults (figure 2).
Status epilepticus and hospital use. Data on use of hos-
pital services by people with CSE in ACE was avail-
able only for Kilifi, where 143/254 (56%) people
with CSE associated with ACE in the community
sought biomedical care for seizures at Kilifi District
Hospital (KDH) at least once. Of these 143
Table 1 Characteristics and prevalence of convulsive status epilepticus in active convulsive epilepsy
Features Agincourt Iganga Kilifi All sites combined
Number with ACE 250 224 722 1,196
Number of CSE cases 78 90 254 422
ACE with CSE, % 31 40 35 35
Study population 82,818 64,172 232,176 379,166
Prevalence of CSE per 1,000 population (95% CI) 0.9 (0.8–1.2) 1.4 (1.1–1.7) 1.1 (0.9–1.2) 1.1 (1.0–1.2)
Adjusted prevalence of CSE per 1,000 population (95% CI) 1.9 (1.7–2.5) 2.8 (2.3–3.5) 2.3 (1.9–2.5) 2.3 (2.1–2.5)
Median age, y (IQR) 26.0 (13.0–38.0) 9.0 (4.0–17.0) 16.0 (9.0–22.0) 15.0 (8.0–24.0)
Male sex, n (%) 39/78 (50) 44/90 (49) 128/254 (50) 211/422 (50)
Characteristics of epilepsy, n (%)
Age at onset of seizures, y (IQR) 9.6 (1.9–20.9) 1.3 (0.5–3.3) 1.5 (0.6–4.0) 1.9 (0.7–6.5)
Focal epilepsy 40/78 (51) 22/90 (24) 108/254 (43) 170/422 (40)
All generalized seizure types 47/78 (60) 67/90 (74) 74/254 (29) 188/422 (45)
All focal seizures types 35/78 (45) 31/90 (34) 193/254 (76) 259/422 (61)
Abnormal EEG 24/53 (45) 18/55 (33) 110/170 (65) 152/278 (55)
Focal EEG features 30/53 (57) 8/55 (15) 46/170 (27) 84/278 (30)
Daily seizures 7/78 (9) 9/90 (10) 37/254 (15) 53/422 (13)
Self-reported AED use, n (%) 42/73 (58) 25/88 (28) 115/253 (45) 182/414 (44)
Case fatality, burns, and social factors, n (%)
Burns 7/78 (9) 6/90 (7) 52/254 (20) 65/422 (15)
Unmarried adults 41/50 (82) 21/28 (75) 78/103 (76) 140/181 (77)
Lack of education 25/77 (32) 37/88 (42) 140/249 (56) 202/414 (49)
Unemployed adults 51/54 (94) 19/23 (83) 61/90 (68) 131/167 (78)
Died 2/78 (3) 5/90 (6) 29/254 (11) 36/422 (9)
Abbreviations: ACE 5 active convulsive epilepsy; AED 5 antiepileptic drug; CI 5 confidence interval; CSE 5 convulsive status epilepticus; IQR 5 inter-
quartile range.
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admissions, 97 (68%) were children; most were
admitted for nonepilepsy reasons. Twelve (12%) chil-
dren with CSE in the community had been hospital-
ized at KDHmore than once. Of the 143 admissions,
46 (32%) were adults, all of whom were admitted
with epilepsy-related complications.
Age at onset of seizures. The median (interquartile
range) age at onset of seizures in years for those with
ACE and CSE was 1.9 (0.7–6.5). The onset of febrile
CSE was earlier (1.2 [0.5–6.3]) than that of nonfe-
brile CSE (6.7 [1.4–18.6]; p , 0.0001). Seizures in
ACE with CSE began earlier in those with a history of
febrile seizures (2.3 [0.7–10.0]) than in those without
(4.0 [1.09–15.0]; p 5 0.0003). Epileptic seizures
began at a younger age in Iganga and Kilifi than in
Agincourt (table 1).
Seizure types. Over half (259, 61%) had focal seizures
in ACE with CSE; the proportion was similar in
males and females (p 5 0.7), and in children and
adults (p 5 0.1), but were more common in febrile
than nonfebrile CSE (146/220 [66%] vs 110/198
[56%]; p 5 0.024). Focal seizures in CSE differed
across sites (p , 0.0001), being most common in
Kilifi (193/254 [76%]). Other specific focal seizure
types are shown in table e-1.
Generalized convulsive and nonconvulsive seiz-
ures in ACE with CSE occurred in 188/422
(45%) study participants and the proportion was
similar in males and females (p 5 0.8) and in chil-
dren and adults (p 5 0.7). The proportion of gen-
eralized seizures in CSE differed across the sites (p,
0.001), being most common in Iganga (67/90
[74%]).
Epileptic seizure semiology and EEG.Of the 278 people
with CSE in ACE who had EEG performed, abnor-
mal EEG patterns occurred in 152 (55%), and abnor-
malities were similar in children and adults (p 5
0.09), but differed with site (p 5 0.001), being com-
monest in Kilifi (110/170 [65%]) (table 1). Focal
EEG features (defined as focal slowing or epileptiform
discharges) were observed in 84/278 (30%) people
with CSE in ACE and did not differ between febrile
and nonfebrile CSE (p 5 0.4). The highest propor-
tion of focal EEG features was seen in Agincourt (30/
53 [57%]), with differences across the sites (p ,
0.0001). Of 125 people reported to have generalized
epileptic seizure semiology in ACE with CSE, 42
(34%) had focal EEG features.
Seizure frequency and AED use. Seizures occurred daily
in 53/422 (13%), weekly in 46/422 (11%), monthly
in 149/422 (35%), and yearly in 174/422 (41%) peo-
ple with CSE in ACE (table e-1). The seizure fre-
quency was not associated with febrile CSE (p 5
0.1). Seizure frequency varied with site (p , 0.001).
AED use was reported by 182/414 (44%) people
with CSE in ACE, and the use varied with site (p 5
0.001), being commonest in Agincourt (42/73 [58%])
(table 1). Blood levels assays showed that 95/352 (27%)
were on AEDs (phenobarbital, carbamazepine, or
phenytoin), representing a sensitivity of 78/155
(50%) for self-reported use. AEDuse was not associated
with seizure frequency for the self-reported use (univar-
iate OR 5 0.89 [95% confidence interval (CI) 0.77–
1.03]; p 5 0.137) but adherence as measured in the
blood was associated with a reduction in seizure fre-
quency (OR5 0.84 [95%CI 0.70–0.99]; p5 0.048).
Figure 2 Prevalence of convulsive status epilepticus associated with active convulsive epilepsy by age group
in Africa
The cumulative prevalence of convulsive status epilepticus in active convulsive epilepsy increased up to 18 years then
declined steadily across 3 sites in sub-Saharan Africa.
Neurology 84 May 5, 2015 1841
ª 2015 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
Risk factors associated with status epilepticus. Several
factors were associated with a higher probability of
having CSE in those with ACE compared to those
with ACE without CSE in the pooled analysis across
all the sites. These included history of acute enceph-
alopathy, neurologic and learning impairments, and
presence of exposure to malaria and HIV in plasma
(tables 2 and 3). History of previous hospitalization
appeared to be protective against developing CSE in
ACE. Site-specific risk factors are shown in table e-2.
A summated score for number of infections de-
tected across all sites was independently associated
with CSE in ACE for antibodies to malaria schizonts
(OR 5 1.84 [95% CI 1.16–2.93]; p 5 0.010) and
HIV (OR 5 2.55 [95% CI 1.22–5.30]; p 5 0.012).
Associations for individual infections are shown in
table 3. These infections were independently associ-
ated with CSE in ACE in Kilifi (OR5 3.47 [95% CI
1.61–7.45]; p 5 0.001 for malaria and OR 5 3.49
[95% CI 1.10–11.08]; p 5 0.034 for HIV), but not
the other 2 sites (table e-2).
Consequences of CSE in those with ACE. Case fatality
proportion. After 3 years, 36/422 (9%) with CSE in
ACE had died, in similar proportions to those with
ACE without CSE (77/774 [10%]; p5 0.4) but with
differences across sites (p , 0.026), being most com-
mon in Kilifi (29/254 [11%]) (table 1). Case fatality
was not associated with adherence to AEDs as mea-
sured in blood (p 5 0.4), but with cognitive impair-
ments (p , 0.001).
Burns. Burns were reported in 65/422 (15%) peo-
ple with CSE in ACE, similar to that of those with
ACE without CSE (142/762 [19%]; p 5 0.2), but
greater than community controls without ACE (58/
1,016 [6%]; p , 0.001). The proportion with burns
differed across the sites (p 5 0.002). Surprisingly,
adherence to AEDs as measured in blood was posi-
tively associated with burns (OR 5 1.70 [95% CI
1.22–2.38]; p 5 0.002).
Lack of education. Lack of formal education was re-
ported in 202/414 (49%) people with CSE in ACE,
similar to those with ACE without CSE (337/763
[44%]; p 5 0.1), but was greater than in community
controls without ACE (272/1,010 [27%]; p ,
0.001). Lack of formal education differed across the
sites (p, 0.001), being more common in Kilifi (140/
249 [56%]) (table 1).
Marriage prospects. Being single was reported in
140/181 (77%) adults with CSE in ACE, greater
than in those with ACE without CSE (242/390
[62%]; p , 0.0001) and in community controls
without ACE (195/475 [41.1%]; p , 0.001). Being
single was significantly associated with adherence to
AEDs as measured in blood (univariate OR 5 1.65
[95% CI 1.25–2.17]; p , 0.0001). Being unmarried
did not differ across the sites (p 5 0.7) (table 1).
Unemployment. Unemployment in adults with CSE
in ACE was similar to those without CSE (131/167
[78%] vs 291/405 [72%]; p 5 0.1), but significantly
greater than that of community controls without
ACE (297/487 [61%]; p , 0.001). Unemployment
was not associated with adherence (p 5 0.9). Unem-
ployment differed across the sites (p, 0.0001), being
most common in Agincourt (51/54 [94%]) (table 1).
Table 2 Pooled univariate and adjusted analysis of the medical risk factors associated with convulsive status epilepticus among people with
active convulsive epilepsy for all sites combined
Variable People without CSE (%) People with CSE (%) Unadjusted OR (95% CI) p Value Adjusted OR (95% CI)a p Value
Medical history
Febrile seizures 90/762 (12) 54/415 (13) 1.12 (0.77–1.60) 0.548 1.13 (0.77–1.64) 0.536
Seizures in siblings 60/768 (8) 33/421 (8) 1.00 (0.64–1.56) 0.987 0.87 (0.54–1.40) 0.563
Seizures in parents 25/767 (3) 16/421 (4) 1.17 (0.62–2.22) 0.625 1.20 (0.63–2.29) 0.585
Adverse perinatal events 29/358 (8) 23/249 (9) 1.15 (0.65–2.05) 0.623 1.16 (0.65–2.08) 0.614
Abnormal pregnancy 57/358 (16) 44/249 (18) 1.13 (0.74–1.74) 0.569 1.06 (0.68–1.67) 0.785
Acute encephalopathy 9/765 (1) 190/418 (45) 70.00 (35.29–138.83) ,0.0001 73.57 (35.45–152.67) ,0.001
Previous hospitalization 458/768 (60) 203/420 (48) 0.63 (0.49–0.80) ,0.0001 0.69 (0.54–0.89) 0.004
Malnutrition 134/765 (18) 67/417 (16) 0.90 (0.65–1.24) 0.526 0.82 (0.58–1.15) 0.253
Learning difficulties 169/768 (22) 146/419 (35) 1.90 (1.46–2.47) ,0.001 1.77 (1.32–2.38) ,0.001
Neurologic deficits 116/767 (15) 106/419 (25) 1.90 (1.41–2.55) ,0.0001 1.75 (1.28–2.40) 0.001
Drug abuse 61/768 (8) 22/419 (5) 0.64 (0.39–1.06) 0.084 0.78 (0.48–1.33) 0.363
Visits traditional healers 474/726 (65) 278/390 (71) 1.32 (1.01–1.72) 0.042 1.30 (0.98–1.72) 0.071
Self-reported AED use 317/754 (42) 182/414 (44) 1.08 (0.85–1.38) 0.526 1.18 (0.91–1.52) 0.219
Abbreviations: AED 5 antiepileptic drug; CI 5 confidence interval; CSE 5 convulsive status epilepticus; OR 5 odds ratio.
a Adjusted for age, sex, site, lack of education, and marital status for adults.
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DISCUSSION The adjusted prevalence of CSE in
people with ACE in Africa is high (2.3 per 1,000),
and the true burden of all CSE may be greater, as
these estimates only represent that associated with
ACE, which does not include acute symptomatic seiz-
ures and deaths after an episode of CSE. CSE was
associated with history of acute encephalopathy, an
absence of previous hospitalization, underlying neu-
rologic impairments, and presence of antibody titers
to falciparum malaria and HIV. Risk factors associ-
ated with CSE in ACE differed across the sites.
CSE is more common in Africa than in other parts
of the world.17 Our estimates of CSE associated with
epilepsy are comparable with those reported in studies
from the United States (0.5–2.5 per 1,000),1,18 where
nonconvulsive epilepsies may have been included in
some studies and case ascertainment may have been
better as they are less hampered by logistical con-
straints. The prevalence was highest in Iganga, where
family history of seizures was an important risk factor,
suggesting shared environmental or genetic factors.
Use of AEDs and hospital services in this study were
low, suggesting the need to apply educational inter-
ventions to encourage use of health services for man-
agement of prolonged seizures.19
Among people with CSE in ACE, seizures began
earlier in those with febrile illnesses than in those
without, probably related to infectious causes of
CSE in childhood.7,20 An early occurrence of CSE
for those with a history of febrile illness may also
suggest a genetic susceptibility for acute febrile seiz-
ures.21,22 The difference in age at onset between sites
suggests different age-dependent risk factors, some of
which may increase case fatality rate, particularly in
children with CSE.4
People with ACE with CSE in Agincourt and
Iganga had a particularly high proportion of general-
ized seizures, but a third had focal EEG features and
could have rapidly generalized. Generalized pro-
longed seizures are thought to be associated with a
good outcome with appropriate treatment,23 while
focal seizures may be a marker of underlying prevent-
able causes or regional atrophy on MRI caused by
prolonged seizures.24
Neurologic and cognitive deficits were important
risk factors of CSE in those with ACE, and could
be markers of underlying brain damage. A history
of acute encephalopathy was associated with CSE,
as would be expected in those hospitalized with
CNS infections,7 also supported by significant pres-
ence of antibodies to falciparum malaria and HIV.
Previous use of hospital facilities appeared protective
against CSE, and this may be explained by some peo-
ple who are likely to live near the hospitals or adhere
to AEDs. Visiting a traditional healer may have de-
layed conventional treatment, with seizures leading to
CSE in some people with ACE.
Exposure to falciparum malaria and HIV was asso-
ciated with CSE in ACE and these 2 infections may
interact.25 We previously found that over half of hos-
pitalized CSE cases in children was related to malaria7
and recently demonstrated that over 90% episodes of
CSE in parasitemic children are caused by malaria.26
The differences in risk factors across sites suggest that
specific preventative strategies and treatment options
should be applied for different sites; alternatively, this
Table 3 Pooled univariate and adjusted analysis of the medical and laboratory risk factors associated with convulsive status epilepticus
among people with active convulsive epilepsy for all sites combined
Variable People without CSE (%) People with CSE (%) Unadjusted OR (95% CI) p Value Adjusted OR (95% CI)a p Value
Blood level AED 182/632 (29) 95/352 (27) 0.91 (0.68–1.22) 0.545 0.92 (0.68–1.25) 0.585
Abnormal EEG 277/515 (54) 152/278 (55) 1.04 (0.77–1.39) 0.810 0.91 (0.67–1.24) 0.529
Focal epilepsy 290/773 (38) 170/422 (40) 1.12 (0.88–1.43) 0.347 1.12 (0.87–1.45) 0.369
Eats pork 172/764 (23) 67/414 (16) 0.66 (0.49–0.91) 0.010 0.78 (0.56–1.09) 0.145
Head injury before seizures 28/739 (4) 7/409 (2) 0.44 (0.19–1.02) 0.056 0.65 (0.28–1.55) 0.337
Hypertension 25/767 (3) 5/421 (1) 0.36 (0.14–0.94) 0.037 0.80 (0.29–2.22) 0.666
Malaria schizont 216/320 (68) 131/176 (74) 1.40 (0.93–2.12) 0.108 1.58 (1.02–2.43) 0.040
HIV 21/314 (7) 19/173 (11) 1.72 (0.90–3.30) 0.102 2.12 (1.04–4.31) 0.039
Malaria schizont and HIV 15/320 (5) 8/176 (5) 0.97 (0.40–2.33) 0.943 1.39 (0.52–3.69) 0.511
Onchocerciasis 6/46 (13) 4/36 (11) 0.83 (0.22–3.21) 0.791 0.81 (0.20–3.24) 0.761
Toxocariasis 88/320 (28) 59/176 (34) 1.33 (0.89–1.98) 0.160 3.90 (0.51–29.79) 0.190
Toxoplasmosis 87/320 (27) 37/176 (21) 0.71 (0.46–1.11) 0.130 0.80 (0.50–1.29) 0.372
Taeniasis 1/46 (2) 1/36 (3) 1.29 (0.08–21.29) 0.861 1.55 (0.09–28.12) 0.765
Abbreviations: AED 5 antiepileptic drug; CI 5 confidence interval; CSE 5 convulsive status epilepticus; OR 5 odds ratio.
a Adjusted for age, sex, site, lack of education, and marital status for adults.
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may be explained by the small numbers at some sites,
different field assistants asking questions, and differ-
ences in medical services. These results may only
apply in other African countries with similar ecolog-
ical, cultural, and sociodemographic characteristics.
Medical and psychosocial detrimental consequen-
ces were similar in those with ACE with and without
CSE but more common than in the general popula-
tion. The mortality was low because this represents
a cohort who have survived CSE, which occurred dur-
ing childhood and was associated with febrile ill-
nesses.7 Case fatality was lower than in CSE in
Richmond, Virginia, where there may have been
more accurate documentation and longer follow-up
period than in our study. This African cohort
included CSE survivors during the survey.4 Case fatal-
ity was increased in those with cognitive impairment,
suggesting that underlying comorbidities, including
psychiatric problems,27 may increase the risk of death
in people with CSE in ACE. Adherence to AEDs
appeared to increase the risk of some social conse-
quences of CSE, supporting the hypotheses that these
occur in severe epilepsy. Those using AEDs and with
severe epilepsy may be stigmatized, affecting marriage
prospects.
The strength of this work is that we used commu-
nity data from multiple sites, and there is detailed
description of risk factors and consequences of CSE.
The study reported estimates for CSE in ACE only,
and yet non-CSE may account for over 50% of the
cases of status epilepticus.28 Recall bias and case fatal-
ity prior to the survey could have caused underesti-
mation of prevalence. This is a cross-sectional study
and future prospective community incidence studies
of CSE and its consequences are required to provide
reliable estimates.
CSE is common in people with ACE in Africa,
with estimates greater than in high-income countries,
and is associated with focal clinical features suggestive
of underlying preventable causes. Underlying neuro-
logic impairments and CNS infections such as falci-
parum malaria are important associations with CSE
in people with ACE. Some associations differ across
countries, suggesting different strategies and control
measures are required for specific sites. CSE in ACE
is associated with detrimental effects, similar to that
seen in ACE without CSE, but greater than in the
general population and thus should be addressed.
Future prospective studies are required to provide
reliable estimates and explore feasible control and
treatment measures.
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